ArticleCurrent neurology and neuroscience reports2008
Controversies in behavioral neurology: the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia.
Article in Current neurology and neuroscience reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.Journal of Alzheimer's disease : JAD · 2022Review
- Caregiver and care recipient characteristics as predictors of psychotropic medication use in community-dwelling dementia patients.Aging & mental health · 2016Article
- Antipsychotic Use and Risk of Nursing Home Admission Among Dual-Eligible Medicare Beneficiaries: A Propensity-Matched Study.Drugs - real world outcomes · 2015Article
- Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.Sleep medicine clinics · 2013Article
- Efficacy and safety of antidepressant drugs in patients with dementia.Current neurology and neuroscience reports · 2011Article
- Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.Journal of molecular neuroscience : MN · 2011Review
- Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.Neurodegenerative disease management · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
"Atypical" antipsychotic drugs are widely used in patients with neurobehavioral disturbances related to dementia. Recent reports have highlighted the risks of these agents, including increased mortality, and the US Food and Drug Administration (FDA) has issued black-box warnings concerning their use. Studies of efficacy have shown only limited evidence that these drugs are more effective than placebo in controlling abnormal behaviors or improving the lives of patients with dementia and their caregivers. Recent evidence suggests that the older, "typical" antipsychotic drugs have at least as much risk as the atypical agents, and FDA warnings have been extended to these agents. In managing the behavioral disturbances of demented patients, clinicians must weigh the benefits and risks of these agents, use them only for severely disruptive behaviors, discontinue medications when ineffective, and inform families of the benefits and risks of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.